Novavax：慘遭重創的 COVID-19 寵兒 (NASDAQ:NVAX)
· seekingalpha.com
Novavax 在後疫情時代被嚴重低估，目前企業價值約為 7.16 億美元。請閱讀為何我現在給予 NVAX 股票「買入」評等。
Novavax ( NVAX ) is a biotechnology company that was, during the COVID-19 time period, valued at over $19.5 billion; now it trades at just around $1.22 billion ...